Applying recession investing strategies for growth during a bear market and recessionary times is challenging. However, private hot growth-stage startups that are developing products that highly disrupt industries and change the face of technology can offer investors an excellent alternative to publicly traded companies and provide profits from a bear market.

​

Selecting hot growth-stage startups that within 2 to 3 years can achieve $billions in valuation based on a successful initial public offering (IPO) is a much-sought goal. This strategy presents a means of jumping over the economic downturn in a bear market. It allows investors to receive profit rewards by stock participation in an IPO that occurs at a time when economic recovery has been established, and a new bull market is in full power mode.

​

This successful approach is based upon diversifying one’s investment strategy beyond the public stock market during a bear market and recessionary times. Hot growth-stage startups developing products and markets that change the face of technology, bringing positive but disruptive technologies to market, and offer investors an excellent means to circumvent the public stock markets and produce profits from a bear market.

​

Within this context of recession investing strategies, BCM Industries (BCM), one of the leading, private, hot growth-stage startups is bringing to market two new major product lines. Both product lines will highly disrupt industries and change the face of technology.

​

First is the forthcoming arrival of the Tissue Operating Device (TOD™), which performs tissue computing with live neural network processing. Tissue Computing can perform complex and larger processing tasks 1,000 times faster than a standard digital computer. The arrival of Tissue processing technology will impact everyone and everything.

​

The second is Autologous Regenerative Tissue Replacement (ARTR™), which provides regenerative cell repair for human livers, lungs, kidneys, and pancreas. This disruptive technology can eliminate the need for organ transplants. It is also being expanded to address regenerative tissue repair of mussels, joints, and bones.

​

To learn more, review the BCM Industries website. This is not an offer to buy or sell any security. An investment in the Company involves risk. To obtain details on private investment opportunities contact a BCM representative or email: support@BCMIndustries.com.

​

Click to view or download

BCM Private Investment Opportunities

​

Investing-Tissue Computing-The Next Leap Forward-Briefing

​

​

​

​